TBPH insider filing: CFO tax-withholding of 18,627 shares at $17.90

Q: What does the transaction code "F" mean in the Theravance Biopharma (TBPH) Form 4?

Transaction code "F" indicates shares were withheld to pay taxes due upon the vesting of previously granted restricted stock units, rather than sold in the open market.

Q: At what price were the Theravance Biopharma (TBPH) shares withheld in this Form 4?

The 18,627 ordinary shares were withheld at a price of $17.90 per share in connection with the tax-withholding transaction.

Q: Did the Theravance Biopharma (TBPH) insider sell shares on the open market?

No. The filing states the share withholding was with the issuer to cover tax obligations and did not involve an open market transaction .

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by its SVP & Chief Financial Officer on 11/20/2025. The officer had 18,627 ordinary shares withheld at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from the vesting of previously granted restricted stock units.

After this tax-withholding event, the officer directly beneficially owned 336,795 ordinary shares. The explanation clarifies that this was a share withholding with the issuer and did not involve an open market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sawaf Aziz

Role SVP & CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	18,627	$17.90	$333K

Holdings After Transaction: Ordinary Shares — 336,795 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/24/2025 - 06:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawaf Aziz

(Last)

(First)

(Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP & CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/20/2025		F		18,627⁽¹⁾	D	$17.9	336,795	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Corinna Liebowitz, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Theravance Biopharma (TBPH) report in this Form 4?

The SVP & Chief Financial Officer reported a transaction on 11/20/2025 where 18,627 ordinary shares were withheld to satisfy tax obligations from vested restricted stock units.

What does the transaction code "F" mean in the Theravance Biopharma (TBPH) Form 4?

Transaction code "F" indicates shares were withheld to pay taxes due upon the vesting of previously granted restricted stock units, rather than sold in the open market.

At what price were the Theravance Biopharma (TBPH) shares withheld in this Form 4?

The 18,627 ordinary shares were withheld at a price of $17.90 per share in connection with the tax-withholding transaction.

How many Theravance Biopharma (TBPH) shares does the officer own after this transaction?

Following the reported transaction, the SVP & Chief Financial Officer directly beneficially owned 336,795 ordinary shares of Theravance Biopharma, Inc.

Did the Theravance Biopharma (TBPH) insider sell shares on the open market?

No. The filing states the share withholding was with the issuer to cover tax obligations and did not involve an open market transaction.

Who is the reporting person in this Theravance Biopharma (TBPH) Form 4?

The reporting person is an officer of Theravance Biopharma, Inc., serving as SVP & Chief Financial Officer.